Gapping up
In reaction to strong earnings/guidance:
In reaction to strong earnings/guidance:
- CBRL +2.4%, AGTC +1%
M&A news:
- SNAK +32.8% (to sell its frozen business for $50 mln; strategic and financial review remains ongoing)
- JWN +6% (reports the company to go private)
Select JWN peers showing strength:
- DDS +4%, SHLD +1.3%, SHOS +1.2%, M +1.2%, JCP +0.7%
Other news:
- BVXV +18.9% (continued strength)
- ALDX +12.8% (continued strength)
- CNC +5.6% (Centene to acquire substantially all of the assets of Fidelis Care for $3.75 bln - will become Centene's health plan in New York State; companies to host conference call at 5:00 PM ET today)
- ZFGN +4.7% (announces initiation of ZAF-1061-201, the Co's Phase 2 clinical trial evaluating ZGN-1061 in patients with type 2 diabetes)
- OTIC +4.1% (unveils set of immediate actions to preserve capital, extend its cash runway, and build shareholder value)
- GTXI +3.6% (top-line results 'demonstrating that a daily dose of enobosarm 3 mg substantially improved stress urinary incontinence')
- TEX +3.4% (Marcato's McGuire discusses Terex position on Delivering Alpha)
- FOLD +3.4% (top-line Phase 3 results for SD-101 in epidermolysis bullosa; study did not meet primary endpoints)
- BCRX +3.3% (prices 15,533,981 shares of its common stock at $5.15 per share)
- PSTI +3.3% (has been issued two new patents by Hong Kong Patents Registry for its cell therapy products relating to two of the company's leading indications, Critical Limb Ischemia (CLI) and muscle regeneration)
- AKCA +3.2% (Akcea Therapeutics and Ionis announce filing of New Drug Submission for Volanesorsen to Health Canada - an investigational medicine for the treatment of familial chylomicronemia syndrome)
- XL +2% (receives full internal model approval from the Bermuda Monetary Authority to calculate the Company's enhanced capital requirements in substitution of the Bermuda Solvency Capital Requirement standard formula)
- ARRY +1.8% (Point72 Asset Management increases passive stake to 5.4%)
- CLVS +1.3% (publication of data from the Phase 3 ARIEL3 study of rucaparib for maintenance treatment of advanced ovarian cancer in The Lancet)
- BBRY +1.3% (BlackBerry and Timex Group enter into a patent license agreement)
- FGEN +1.3% (announces 'positive' results from the company's Phase 2b study in patients with idiopathic pulmonary fibrosis)
- NCS +1.1% (Director purchased 30K shares on 9/11)
- JUNO +1% (granted orphan drug designation by the FDA for its compound for the treatment of follicular lymphoma)
Analyst comments:
- FINL +4.6% (upgraded to Positive from Neutral at Susquehanna)
- SQM +3.4% (upgraded to Buy from Neutral at BofA/Merrill)
- ADMP +2.8% (initiated with a Outperform at Raymond James)
- AMAT +1.6% (upgraded to Buy from Neutral at Goldman)
- MU +0.9% (upgraded to Buy from Neutral at Goldman)